יום חמישי, 18 בספטמבר 2014

BEN GURION UNIVERSITY -  first Israeli university to become member of US National Academy of Inventors
 
 
 
The Beersheba institution of higher learning was recognized as being one of the 100 leading universities in the world for the number of applied US patents. Students
Students at Hebrew University. (photo credit:MARC ISRAEL SELLEM/THE JERUSALEM POST)
             
            

 

  

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Israeli researchers: Not so fast on artificial sweetener settled science

 
Find artificial sweeteners boost diabetes risk — Will anti-Israel academic boycotters ignore these
findings?
     
Posted by    Thursday, September 18, 2014     

 
http://www.wpxi.com/videos/news/artificial-sweetener-could-promote-diabetes/vCsRgB/

It’s a good thing we still have scientists who refuse to accept settled science and scientific consensus, and keep on digging and questioning prevailing wisdoms.
It seems that many of such scientists are in Israel, perhaps because politicized scientific conformity is not as prized in the “start-up nation” as it is in Euorpe and the U.S.

One example from Israel we reported on previously was Nobel Prize in Chemistry awarded scientific denier:
Israeli scientist Daniel Shechtman won the 2011 Nobel Prize in chemistry on Wednesday for his discovery of quasicrystals, a mosaic-like chemical structure that researchers previously thought was impossible.
The Royal Swedish Academy of Sciences said Shechtman’s discovery in 1982 fundamentally changed the way chemists look at solid matter. It initially faced strong objections from the scientific community, and even got him kicked out of his research group in the United States.
Now another, from AFP via Times of Israel, Sweeteners boost diabetes risk, Israeli study finds:

Promoted as an aid to good health, artificial sweeteners may in fact be boosting diabetes risk, said an Israeli study Wednesday that urged a rethink of their widespread use and endorsement….
After leaving a sensation of sweetness on the tongue, NAS [Non-caloric artificial sweeteners] molecules pass through the intestinal tract without being absorbed.
This explains why, unlike sugar, they add negligibly, if at all, to the calorie count.
But Israeli scientists reported in the journal Nature that experiments on lab mice and a small group of humans found NAS disrupted the makeup and function of gut bacteria, and actually hastened glucose intolerance.
“Artificial sweeteners were extensively introduced into our diets with the intention of reducing caloric intake and normalizing blood glucose levels without compromising the human ‘sweet tooth,’” the paper said.
“Our findings suggest that NAS may have directly contributed to enhancing the exact epidemic that they themselves were intended to fight,” it said bluntly.
Scientists led by Eran Elinav and Eran Segal of the Weizmann Institute of Science in Israel added three commonly-used types of NAS — aspartame, sucralose or saccharin — to the drinking water of mice in body-size appropriate doses equivalent to recommended maximum human intake.

Oh, and one more thing.
The Weizmann Institute of Science is subject to the academic boycott of Israel championed by Steven Salaita, the controversial almost-U. Illinois professor and his supporters at the American Studies Association and in some pockets of academia.
http://commons.wikimedia.org/wiki/File:Weizmann_Institute_of_Science40.JPG
[Weizmann Institute of Science via Wikimedia Commons]
The academic BDS supporters should ignore these Israeli research findings, in the spirit of anti-Zionist solidarity.

יום שני, 1 בספטמבר 2014

Israeli IPO’s World-Beating 73% Surge Leads August Rally
 
 
Mobileye has surged 73 percent to $43.22 since listing in New York on July 31, the biggest rally among all companies globally that raised $500 million or more in the past three months. Caesarstone Sdot-Yam Ltd. (CSTE), the maker of quartz counter-tops, climbed 20 percent in August, the second-best performance on the Bloomberg Israel-U.S. Equity Index, which rose 4.8 percent.
While signs have emerged that the Gaza fighting is starting to curb output at some Israeli businesses, hurt tourism and cut into consumer spending, investors have shown little concern, instead bidding up stocks in line with gains being posted in the U.S. and other major global markets. The performance of Mobileye and Caesarstone, which has more than tripled since its 2012 listing, could help bolster demand for more Israeli initial public offerings, according to Josef Schuster, the founder of Chicago-based IPOX Schuster LLC.
“Momentum drives everything right now,” Schuster said by phone Aug. 28. “Mobileye and Caesarstone, if you held that, you made a lot of money.”
The Nasdaq Composite Index (CCMP) advanced 4.8 percent this month, while the Standard and Poor’s 500 Index gained 3.8 percent, breaking the 2,000 mark on Aug. 26, 27 and 29.
Investors are pouring money into equities on optimism the U.S. economy is strengthening and as European Central Bank President Mario Draghi signaled policy makers may introduce an asset-buying plan to bolster growth amid slowing inflation.

Record IPO

Executives at Mobileye didn’t respond to a request for comment made after business hours in Israel.
Mobileye’s $1 billion IPO was the biggest in the U.S. by an Israeli company on record, part of a rush of deals last month. Six Israeli companies have gone public in the U.S. this year, according to data compiled by Bloomberg. Eight more have offerings pending.
“We’re continuing to see moderate appetite for IPOs in the U.S. by Israeli companies,” Phyllis Korff, a lawyer at Skadden Arps, Slate, Meagher & Flom LLP in New York, said in an e-mail. “This activity could continue through the end of 2014 and into the first quarter of 2015,” said Korff, who worked on the Mobileye offering.
The Jerusalem-based technology company, whose customers include luxury electric-carmaker Tesla Motors Inc., posted 2013 net income of $19.9 million following two years of losses, according to its IPO prospectus. Revenue in 2013 was $81.2 million, more than double the figure from 2012.

Rate Cut

“People are buying it on the hope of great growth,” Brian Krawez, who oversees $3 billion at Scotts Valley, California-based Scharf Investments, said by phone Aug. 28. “People were very skeptical of the stock market, they missed a lot of the rally. Now with the market up, they’re moving cash from the sidelines.”
While global financial markets have shrugged off fighting in Gaza, it has begun to take its toll on Israel’s economy. The Bank of Israel unexpectedly cut interest rates to a record low on Aug. 25 in an attempt to boost an economy already hit by slowing exports.
Israeli growth slowed in the second quarter to 1.7 percent from 2.8 percent in the previous three months, as exports, which account for about a third of the economy, tumbled 18 percent, according to official data released Aug. 17.

Stock Gains

An Egyptian-brokered truce that started Aug. 26 halted seven weeks of fighting that killed more than 2,100 Palestinians and 70 on the Israeli side, according to official tallies.
The local TA-25 Index (TA-25) rose 0.6 percent this month, trailing the 4.8 percent gain on the Bloomberg Israel-US Index. Tel Aviv stocks have appreciated 5.3 percent this year, compared with an 11 percent advance for U.S.-listed Israeli stocks.
Caesarstone, which makes quartz kitchen counter-tops, surged this month after issuing a new full-year sales estimate that surpassed analysts’ projections. The stock has appreciated 373 percent since its IPO in March of 2012.
“They’re just executing extremely well and the stock was cheap at the onset,” Schuster said. “It’s one of those stocks you wish you had held on to forever.” ((An earlier version of this story corrected the law firm’s name in the ninth paragraph.)) 
 
 

יום שבת, 30 באוגוסט 2014

GOOD NEWS FROM TINNY ISRAEL FOR RELIEF OF MILLIONS  PEOPLE WORLDWIDE

Came from Haifa University,  Israel

EXCLUSIVE: A cure for ALL cancers is on the way as scientists make major breakthrough

MILLIONS of cancer ­sufferers have been given fresh hope of a cure after ground-breaking research.

Scientists have made huge leaps in cancer research
Scientists have made huge leaps in cancer research [picposedbymodel REUTERS]

The breakthrough came in a 16-year study of the only ­animal immune to cancer.
The discovery by an Israeli specialist was last night hailed as “radical and potentially life-changing”.
In a world first, Professor Aaron Avivi and his team found that cells from the blind mole rat and its cousin the naked mole rat secrete a substance that destroys cancer cells in mammals – including humans.
Experts think harvesting this substance and making it safe to digest could wipe out a disease that kills eight million people each year worldwide. Last night Prof Avivi, of Haifa University in Israel was heading to London where he is due  to present his findings to professionals.
His radical approach studied the two species of rat that both live mostly underground – which the team discovered had led to a dramatic evolution of their metabolism.
Blind mole rats outlive other rodents by at least 20 years with no outward signs of ageing. Researchers have never located a cancerous tumour on one of them.
cancer
Millions of cancer sufferers are given fresh hope for a cure [picposedby model GETTY]

The team tested the underground rodents and regular mice and rats with two potent carcinogens. Ordinary mice and rats developed tumours – none was found in the subterranean rats.
The study, published in the widely respected BMC Biology Journal, concluded: “Blind mole rats are resistant to spontaneous cancer but also to experimentally induced cancer.
“It shows the unique ability of the blind mole rat to inhibit growth and kill cancer cells, but not normal cells. It has evolved efficient anti-cancer mechanisms.
“Exploring the molecular mechanisms may hold the key for understanding the nature of resistance to cancer and identify new strategies for treating humans.”
The study was described as “exciting” by Prof Penella Woll, of the University of Sheffield’s department of oncology. She said: “Other researchers have taken a similar approach, studying sea creatures with intrinsic cancer resistance to develop the anti-cancer drug ­trabectedin – so we know that this can succeed.”
Cancer care specialist Prof Sam Ahmedzai said: “If Prof Avivi’s research can help us identify what genetic changes have occurred in the blind mole rat – and if that knowledge can allow us to modify humans’ genetic codes – then this is a radically and potentially life-saving treatment.
“There will undoubtedly be many years of extracting the relevant parts of the mole rats’ genetic differences and then – the most difficult aspect – bringing those gene extracts into humans. Prof Avivi is to be congratulated on opening up an exciting new phase of research.”
Oliver Childs, of Cancer Research UK, added: “It’s a long way off, but it will be interesting to see if further research can find a way to help prevent or treat cancer in humans.”
In Britain, nearly 350,000 people are diagnosed with cancer every year. Macmillan Cancer Support predicts the number who will get cancer during their lifetime will rise to nearly half the UK population by 2020. Other studies forecast global cancer rates will increase to 16 million new cases by the same year.

יום שישי, 20 ביוני 2014

High education institue in Israel ranked among the 100 global top institutions

Bloomberg names Technion one of top high tech hubs

 
 
 
 
The Computer Science Faculty building, named after Taub, in the Technion Institute for Science, Haifa, Israel ( Beny Shlevich )            
Haifa-based institution the only non-US university to make the cut in the prestigious ranking
Technion – Israel Institute of Technology is among the top ten tech hubs for future CEOs, according to a ranking by the financial news network Bloomberg, the only non-US instution to make the cut
 
Bloomberg rated the Haifa-based Technion seventh, tied with MIT, Rice University and the University of Texas, Austin based on the alma maters of 250 CEOs of American tech companies with a net value upwards of $1 billion  Princeton, Harvard and Stanford topped the ranking.
 
 
Founded in 1912, Technion is the oldest higher education institution in the country. It offers degrees in science and engineering, and a number of related fields. It is known for its long-standing collaboration with the IDF on development of advanced battlefield technologies, as well as being the chief manpower provider to Israel's tech private sector.  Earlier this month, a Chinese survey put three academic institutions in the top 100 global annual rankings of universities  Israel was placed behind France, which has four academic institutions in the list, thus according to the survey.
 
The Hebrew University of Jerusalem ranks in the 59th place, followed by the Technion in Haifa, 77, one spot higher than in 2012. Weizmann Institute is at the 92nd place

Technion-Israel Institute of Technology developed device uses breath to detect lung cancer

With lung cancer a leading cause of death, more efficient detection methods could make a difference
 
 
The Computer Science Faculty building, named after Taub, in the Technion Institute for Science, Haifa, Israel ( Beny Shlevich )


A cancer detection device that looks for malignant tumors by analyzing a patient's breath is set to be commercialized following a study on the Technion-developed "NaNose" system that proved 90 percent accuracy




A chip at the center of the device, which looks like a Breathalyzer, detects a special "odor" created by cancer cells. The NaNose system can detect both benign and malignant tumors faster and cheaper than can other detection technologies, said Dr. Hossam Haick of the Technion - the Israeli Institute of Technology - the Times of Israel reported
“Current cancer diagnosis techniques are ineffective and impractical.” NaNose technology, he said, “could facilitate faster therapeutic intervention, replacing expensive and time-consuming clinical follow-up that would eventually lead to the same intervention.”   Haick and fellow researchers Nir Peled of Tel Aviv University's Sackler Faculty of Medicine and Professor Fred Hirsch of the University of Colorado School of Medicine presented the new study on the NaNose-based system at a conference in Chicago
US government statistics show that lung cancer kills more Americans annually that the next three most common cancers combined – colon, breast, and pancreatic. One of the reasons behind this statistic is that lunng cancer is difficult to detect.   Early-stage lung cancer has previously only been detected through extensive analyses involving blood tests, biopsies, CT scans, ultrasounds, and other procedures. Peled stressed that “Lung cancer is responsible for almost 2,000 deaths in Israel annually, a third of all cancer-related deaths. Lung cancer diagnoses require invasive procedures such as bronchoscopies, computer-guided biopsies or surgery
 
Haick explained that “mostly, the patient arrives for diagnosis when the symptoms of the sickness have already begun to appear The NaNose-based device, however, needs only the patient to breath in order to take a sample and create an initial diagnosis. Lung cancer tumors produce chemicals that evaporate and produce a scent detectable by the device. In four out of five cases the device differentiates between benign and malignant growths in the lungs. The NaNose technology was licensed last year by Boston's Alpha Szenszor, which hopes to introduce the device to the market in the next several years
 

יום שלישי, 10 ביוני 2014

Israeli patient gets new ‘connected’ pacemaker

The Biotronik heart device provides doctors with a clear daily picture of how a patient is doing
         
Get the Start-Up Israel's daily newsletter
and never miss our top stories
  Free Sign up!
With the system, said Ido Mizrahi, a vice president at Biotronik Israel, doctors can keep an eye on their patients’ hearts every day. “Usually a patient will come into the doctor’s office for a checkup once every few months, but with the new technology, they can be remotely examined every day,” Mizrahi said.
The Etrinsa HF-T was implanted last week inside a patient at Barzilai Hospital on the same day that similar groundbreaking operations happened in France and Germany. The system showed its effectiveness within days, according to Mizrahi. “A few days after receiving the implant the patient developed cardiac arrhythmia, which could have led to complications. Instead of waiting weeks to return to the doctor for a follow-up, as patients with ordinary pacemakers would, doctors knew about this patient’s problem right away, and were able to treat it before it could deteriorate.”
With the new cardiac resynchronization therapy pacemaker (CRT-P), said Mizrahi, doctors can get immediate information, such as a patient’s cardiac arrhythmia, to physicians via the mobile Internet. The doctors can immediately detect when there is a problem and intervene before the situation deteriorates. Biotronik, a German-based medical technology company with sales around the world, is the first to apply communications technology to pacemakers. The firm, along with several others, offers remote cardiac resynchronization therapy defibrillators, used to detect asynchronous activity in the heart’s left and right ventricles.
The pacemaker connects to Biotronik’s Home Monitoring system and automatically uploads data. Physicians get regular updates on how the pacemaker is functioning. The data goes into the patient’s file and, using Biotronik software, is crunched and charted. The connected pacemaker does all the work, automatically and works even when the patient is sleeping. According to Biotronik, the radiation emitted by the device is far less than the FDA limit for electronic body monitoring devices.
According to the company, the system is not meant for emergencies. The information is delivered via text messages on the cell network, which are not always delivered immediately. In case of an emergency, Biotronik says, “the patient has to call a doctor in the usual way. Doctors can see how problems develop very early on, so they can detect a problem weeks before the patient begins to feel symptoms,” said Mizrahi. “If a problem does begin to develop, the system will send out yellow and red alerts, ensuring that the doctor is aware of the importance of the situation and allowing the patient to receive care long before they usually would have, on their regular quarterly or semi-annual visit.”
The device is part of the burgeoning digital health/connected health movement, in which health professionals have begun to marshal the power of digital devices to help people live healthier lifestyles, along with enabling doctors, employers and insurance companies to keep tabs on patients. Devices and apps are available to monitor weight, blood pressure, heart rate, cholesterol levels, glucose levels and other data. Sensors that communicate with smartphones or remote servers can read what is going on inside the body and upload it to individuals’ online medical files. Doctors can access the files to get a full picture of the progress clients are making in getting healthier. The collected data can even be used to prevent medical emergencies, with an alarm going off at an emergency rescue service, indicating that the patient needs immediate care.
Israel has been at the forefront of developing connected medical devices, which use sensors connected to devices like glucose meters to read blood sugar levels and upload the data to care practitioners. Large health concerns, such as GE Healthcare, have operated in Israel for years and have worked with numerous Israeli start-ups to develop new apps and devices, such as the oximeter, a blood oxygen monitor developed by Israel’s Oxitone.
According to Dr. Vladimir Khalameizer, director of cardiology at Barzilai, “devices like this allow us to provide the best possible care. The sooner I know about a problem, the faster I can deal with it, and that is exactly what this pacemaker does. I consider it a singular honor that our hospital was chosen among the first to have the opportunity to use this device.”